- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04667910
601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
December 8, 2020 updated by: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
A Randomized, Double Masked, Multicenter, Phase II Study Assessing the Safety and Efficacy of 601 Versus Ranibizumab in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to CRVO
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Following a 14-day maximum screening period, patients will be randomized and followed for approximately 52 weeks.
Treatment visits will be scheduled in 4-week intervals.
After 6 initial monthly injections of 601 or ranibizumab (loading phase), subjects will enter an individualized flexible treatment (IFT) phase (week 24 to week 48).
During the IFT phase, an assessment of disease stability will be performed at each monthly visit and subjects will receive either an injection or not.
Safety and efficacy outcomes will continue to be evaluated up to a period of 52 weeks unless the patient is withdrawn or discontinues the study.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiao rong Li, MD
- Phone Number: +86-022-23346434
- Email: xiaorli@163.com
Study Locations
-
-
TianJing
-
TianJing, TianJing, China, 300384
- TianJing Medical University Eye Hospital
-
Contact:
- Xiaorong Li, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sign informed consent form and willing to be visited at the time specified in the trial
- Male or Female, at least 18 years of age
The study eye must meet the following criteria
- Diagnosed with macular edema secondary to central retinal vein occlusion within 12 months
- BCVA score between 78 and 19 letters, inclusive, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/32 to 20/400)
- CRT ≥ 250μm
- No optometric media opacity and pupil abnormal
- BCVA score ≥ 34 letters in the fellow eye, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/200)
Exclusion Criteria:
For Study Eye:
- Concomitant conditions or ocular disorders in the study eye at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention during the first 12-month study period (e.g. scarring, fibrosis or atrophy of the fovea, dense subfoveal hard exudates, significant hemorrhage obscuring the macular, vitreous hemorrhage, vitreomacular traction, retinal vascular occlusion other than CRVO, retinal detachment, macular hole, or age-related macular degeneration,choroidal neovascularization of any cause, diabetic retinopathy (except mild non-proliferative) and diabetic macular edema). Hemiretinal vein occlusion (HRVO) should be excluded
- iris, chamber angle neovascularization or retinal, optic disc neovascularization
- Previous use of intraocular or periocular steroids within 3 months prior to baseline, or previous use of dexamethasone intravitreal implant within 6 months prior to baseline
- Macular laser photocoagulation (focal/grid),panretinal laser photocoagulation,vitrectomy,radial optic neurotomy arteriovenous sheathotomy,trabeculectomy or keratoplasty in the study eye at any time prior to baseline. Local laser photocoagulation, YAG laser treatment or any other ocular surgeries (e.g. cataract surgery ) in the study eye within 3 months prior to the baseline
- During the screening period, the BCVA is >10 letters improved (the BCVA detected within 24 hours before the administration at day 0 compared with the BCVA at the screening)
- Aphakia (except IOL) or posterior capsular defect (except YAG posterior capsulotomy after intraocular lens implantation surgery)
For Any Eye:
- Any eye has active ocular infections (e.g. blepharitis, conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis)
- Uncontrollable glaucoma (defined as intraocular pressure after antiglaucoma therapy>= 25 mm Hg), or the cup/disk ratio >0.8 in the study eye
- History of intravitreal use of anti-VEGF drugs (e.g. ranibizumab,bevacizumab,aflibercept, conbercept, etc.) in any eye within 3 months prior to baseline
General Exclusion Criteria:
- History of allergy to fluorescein sodium and allergies to protein products for treatment or diagnosis
- History of stroke (cerebrovascular accident), myocardial infarction, active disseminated intravascular coagulation or pronounced bleeding tendency in the past 6 months prior to baseline
- Diagnosed systemic immune diseases (e.g. ankylosing spondylitis, systemic lupus erythematosus, Behcet's disease, rheumatoid arthritis, scleroderma etc.)
- any uncontrolled clinical problem (e.g. AIDS, active hepatitis, serious mental, neurological, cardiovascular, respiratory and other systemic diseases or malignant tumors, etc.). Malignant tumors with no metastasis or recurrence within 5 years or cancers in situ cancers are not excluded.
- Uncontrolled blood pressure control (defined as systolic blood pressure > 160 mmHg or diastolic pressure > 100 mmHg after antihypertensive medication
- History of surgery (except for healed minimally invasive surgery) and/or currently have unhealed wounds, moderate to severe ulcers, fractures, etc. within 1 month prior to baseline
- History of system use of anti-VEGF drugs (e.g. bevacizumab) within 3 months prior to baseline
Laboratory Exclusion Criteria:
- Liver dysfunction (ALT or AST is 2 times higher than the upper limit of normal value in the local laboratory). Renal function impairment (Cr is 1.5 times higher than the upper limit of normal values in the local laboratory)
- Abnormal coagulation function (prothrombin time >= the upper limit of normal value for 3 seconds) and activated partial thromboplastin time >= the upper limit of normal value for 10 seconds);
Other Exclusion Criteria:
- Non-use of effective contraception during childbearing age (except for women with spontaneous admonishment of more than 12 months)
- Pregnancy and lactation women
- Participation in clinical trials of any drug (except vitamins and minerals) or medical devices in the past 1 month or 5 half-lifes if the drug has a long half-life >1 month prior to baseline;
- Researchers think it needs to be ruled out
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 601 1.25mg
|
Solution for injection (intravitreal use)
Other Names:
|
EXPERIMENTAL: Ranibizuman 0.5 mg
|
Solution for injection (intravitreal use)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in best-corrected visual acuity (BCVA) at Week 24
Time Frame: Baseline to Week 24
|
Assessed with ETDRS visual acuity testing charts.
|
Baseline to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in BCVA by visit up to Week 12 and Week 52
Time Frame: Baseline, Week 12 and Week 52
|
Assessed with ETDRS visual acuity testing charts.
|
Baseline, Week 12 and Week 52
|
Proportion of study eyes with a gain ≥ 5, 10 and 15 letters in BCVA by at Week 12, Week 24 and Week 52 compared to baseline
Time Frame: :Baseline, Week 12, Week 24 and Week 52
|
Assessed with ETDRS visual acuity testing charts.
|
:Baseline, Week 12, Week 24 and Week 52
|
Average Change of BCVA From Baseline to Week 4 Through Week 52
Time Frame: Baseline to Week 52
|
Assessed with ETDRS visual acuity testing charts.
|
Baseline to Week 52
|
Average Change of BCVA From Baseline to Week 28 Through Week 52
Time Frame: Week 28 to Week 52
|
Assessed with ETDRS visual acuity testing charts.
|
Week 28 to Week 52
|
Change from baseline in central retina thickness (CRT) at Week 12, Week 24 and Week 52
Time Frame: baseline, Week 12, Week 24 and Week 52
|
OCT (optical coherence tomography) was used to assess central retina thickness (CRT) representing the average retinal thickness of the central 1 mm diameter subfield around the foveal center.
|
baseline, Week 12, Week 24 and Week 52
|
Number of injections from baseline to Week 52
Time Frame: baseline to Week 52
|
Number of administered injections
|
baseline to Week 52
|
Number of injections between Week 24 to Week 52
Time Frame: Week 24 to Week 52
|
Number of administered injections
|
Week 24 to Week 52
|
Incidence of ocular and non-ocular AEs up to Week 52
Time Frame: Baseline to Week 52
|
Incidence of ocular and non-ocular AEs
|
Baseline to Week 52
|
Blood concentrations of 601 at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24,Week 36 and Week 52
Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24,Week 36 and Week 52
|
Steady-state blood concentrations of 601
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24,Week 36 and Week 52
|
Blood concentrations of VEGF at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24,Week 36 and Week 52
Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24,Week 36 and Week 52
|
Detection of VEGF blood concentration.
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24,Week 36 and Week 52
|
Immunogenicity of 601 at Baseline, Week 4, Week 12, Week 24, Week 36 and Week 52
Time Frame: :Baseline, Week 4, Week 12, Week 24, Week 36 and Week 52
|
Detection of blood Anti-drug antibody (ADA) status.
If ADA was positive, Neutralization antibody (Nab) will be tested.
|
:Baseline, Week 4, Week 12, Week 24, Week 36 and Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiao rong Li, MD, TianJing Medical University Eye Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
December 1, 2020
Primary Completion (ANTICIPATED)
July 1, 2022
Study Completion (ANTICIPATED)
January 1, 2023
Study Registration Dates
First Submitted
December 8, 2020
First Submitted That Met QC Criteria
December 8, 2020
First Posted (ACTUAL)
December 16, 2020
Study Record Updates
Last Update Posted (ACTUAL)
December 16, 2020
Last Update Submitted That Met QC Criteria
December 8, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Retinal Vein Occlusion
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- SSGJ-601-CRVO-II-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Retinal Vein Occlusion
-
University of TorontoOntario Research FundUnknownCentral Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Central Retinal Artery Occlusion | Branch Retinal Artery OcclusionCanada
-
University of TorontoPfizer; Unity Health Toronto; Canadian Heart Research Centre; Ontario Association... and other collaboratorsUnknownThrombosis | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Retinal Vein ThrombosisCanada
-
Palo Alto Medical FoundationTerminatedCentral Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Tokyo Medical UniversityUnknownCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionJapan
-
The Emmes Company, LLCNational Eye Institute (NEI); University of California, DavisActive, not recruitingCentral Retinal Vein OcclusionUnited States
-
Universitaire Ziekenhuizen KU LeuvenWithdrawn
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenCompleted
-
Centre Hospitalier Intercommunal CreteilCompletedCentral Retinal Vein OcclusionFrance
-
Fondation Ophtalmologique Adolphe de RothschildBayerActive, not recruiting
Clinical Trials on 601 1.25mg
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...UnknownBranch Retinal Vein OcclusionChina
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...RecruitingBranch Retinal Vein OcclusionChina
-
Joanne Kurtzberg, MDAldagenWithdrawnLysosomal Storage Diseases | Inborn Errors of MetabolismUnited States
-
ADC Therapeutics S.A.TerminatedAdvanced Solid TumorsUnited States
-
C.B. Fleet Company, Inc.CompletedBowel Cleansing Prior to ColonoscopyUnited States
-
National Institute of Allergy and Infectious Diseases...Active, not recruiting
-
Motric BioRecruitingStroke | Multiple Sclerosis | Cerebral Palsy | Spinal Cord Injuries | Dystonia | Muscle Spasticity | Hereditary Spastic Paraplegia | Hypertonia, MuscleUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
TransMolecularUnknownAstrocytoma | Glioblastoma Multiforme | Malignant Glioma | GBM | OligodendrogliomaUnited States
-
Erasca, Inc.Active, not recruitingAdvanced or Metastatic Solid TumorsUnited States